DrugPatentWatch Database Preview

FABIOR Drug Profile

Which patents cover Fabior, and when can generic versions of Fabior launch?

Fabior is a drug marketed by Mayne Pharma and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in FABIOR is tazarotene. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

Summary for FABIOR

US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	89
Clinical Trials:	1
Patent Applications:	4,262
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for FABIOR
DailyMed Link:	FABIOR at DailyMed

Drug patent expirations by year for FABIOR

Pharmacology for FABIOR

Ingredient-type	Retinoids
Drug Class	Retinoid

Synonyms for FABIOR

118292-40-3
15146-EP2275420A1
15146-EP2295055A2
15146-EP2295416A2
15146-EP2298748A2
15146-EP2298764A1
15146-EP2298765A1
15146-EP2298768A1
15146-EP2305642A2
15146-EP2308861A1
15146-EP2311453A1
15146-EP2311808A1
15146-EP2311829A1
15146-EP2314590A1
15146-EP2316832A1
15146-EP2316833A1
292T403
3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester
3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester
4CA-1215
6-(4,4-Dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester
6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester
6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester
6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic Acid Ethyl Ester
6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester
6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylester
81BDR9Y8PS
AB0012671
AB01274801_02
AB01274801-01
AB2000146
ABP000994
AC-755
AC1L1K88
Acnitaz
ACT06773
AGN 190168
AGN-190168
AJ-26850
AK-73028
AKOS015902872
AN-15540
ANW-45265
Avage
Avage (TN)
AX8041205
BC201578
BCP0726000163
BDBM50265951
BIDD:GT0293
BR-73028
BS-1012
C-23771
C12531
C21H21NO2S
CAS-118292-40-3
CC-34651
CHEBI:32184
CHEMBL1657
CJ-24315
CS-1029
CTK8B4490
D01132
D0BM5G
DB00799
DR001785
DSSTox_CID_26691
DSSTox_GSID_46691
DSSTox_RID_81825
DTXSID5046691
EBD38650
Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester
ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate
ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate
Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate
ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate
Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate
ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate
Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate
ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate
Fabior (TN)
FT-0652578
GTPL6952
HE299896
HMS3655K05
HY-15388
I14-1992
KB-80817
LS-130838
MFCD00867628
MLS003915630
MolPort-005-932-693
NCGC00167525-01
NCGC00167525-02
NCGC00167525-03
OGQICQVSFDPSEI-UHFFFAOYSA-N
PubChem24431
Q-102516
RTR-034197
S-7551
s1569
SC-19506
SCHEMBL3134
SMR002096194
SR-01000931253
SR-01000931253-2
ST2419369
Suretin
tazarotene
Tazarotene (Avage)
Tazarotene (JAN/USAN/INN)
Tazarotene [USAN:INN:BAN]
Tazarotene [USAN:INN]
tazaroteno
tazarotenum
Tazorac
Tazorac (TN)
Tazorac, Avage, Zora, Tazarotene
Tazorac;Avage;Zora;Avage
Tazoral
Tox21 112522
Tox21_112522
Tox21_112522_1
TR-034197
UNII-81BDR9Y8PS
ZINC1542199
Zora
Zorac
Zorac (TN)
Zorac\|\|\|Tazorac

US Patents and Regulatory Information for FABIOR

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	FABIOR	tazarotene	AEROSOL, FOAM;TOPICAL	202428-001	May 11, 2012		RX	Yes	Yes	➤ Try a Free Trial	➤ Try a Free Trial	Y			➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

International Patents for FABIOR

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
China	102438590	➤ Try a Free Trial
Japan	6182191	➤ Try a Free Trial
Israel	214520	➤ Try a Free Trial
European Patent Office	2400951	➤ Try a Free Trial
Mexico	2011008912	➤ Try a Free Trial
Australia	2010217190	➤ Try a Free Trial
Mexico	340791	➤ Try a Free Trial
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for FABIOR

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0008	Belgium	➤ Try a Free Trial	PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
/1998	Austria	➤ Try a Free Trial	PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
C/GB98/002	United Kingdom	➤ Try a Free Trial	PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Summary for FABIOR

Pharmacology for FABIOR

Synonyms for FABIOR

For more information try a trial or see the plans and pricing